Back to search results

Observational Study on Blood Test for Early Lung Cancer Detection

This observational study aims to find and confirm blood-based markers (biomarkers) that can help detect lung cancer early in heavy smokers who don't yet have symptoms. Researchers want to develop a blood test to identify those at highest risk. You could be eligible if you are between 30 and 80 years old, are a current or former smoker, and are willing to provide a blood sample. The study is looking for 350 participants and will compare blood samples from people with confirmed lung cancer, people without cancer, people with an indeterminate (uncertain) risk of lung cancer, and people with other smoking-related cancers. The main goal is to see if this blood test can find early-stage lung cancer in heavy smokers without symptoms.

Study design
This is an observational study planning to enroll 350 participants. It will collect samples from four different groups of people.
What's involved
You would need to provide a blood sample. The study observation period is 24 months.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint, biomarker discovery and validation, will be measured from enrollment to the end of the study observation period of 24 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06816121

Identification and Validation of Blood-Based Biomarkers for Early Detection of Asymptomatic Lung Cancer in High-Risk Heavy Smokers

Recruiting
Not specifiedAges 30–80Observational
Everest Detection, Inc.
~350 participants
Updated 2026-04-13 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Biomarker Discovery and Validation for Blood-Based Early Lung Cancer Detection in Heavy Smokers
Measured over From enrollment to the end of the study observation period of 24 months

Conditions

Lung Cancers

Explore related trials

Cancer OtherLung Carcinoma

Where it's being run

1 sites across 1 states
Oklahoma1

Who to contact

Everest Detection Clinical Operations
[email protected]
786.542.2122
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Understands the study and can provide written informed consent
Willing and able to provide a blood sample
Age 30-80
Current or former smoker
Recent CT scan within 3 months AND
No lung nodules (Lung-RADS 1) or benign/stable nodules
Recent CT scan within 12 months AND
Indeterminate lung nodules under active monitoring
Confirmed untreated lung cancer OR
Highly suspicious lung nodules undergoing diagnostic work-up

Exclusion

Cancer diagnosis within the last 5 years
Systemic therapy, radiation, or surgery for cancer within 1 year prior to enrollment
Any history of hematologic malignancies or myelodysplasia
Known infection with HIV, HCV, or HBV
Active pregnancy

What this trial measures

  • Biomarker Discovery and Validation for Blood-Based Early Lung Cancer Detection in Heavy SmokersFrom enrollment to the end of the study observation period of 24 months

    This study aims to discover and optimize biomarkers for a blood-based test that detects early-stage lung cancer in heavy smokers without symptoms. Researchers will develop and validate the test using blood samples from individuals with lung cancer, those at varying screening risk levels (Lung-RADS 1-4), and heavy smokers with smoking-related cancers.